Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) in Combination with KEYTRUDA (Pembrolizumab) in Advanced/Metastatic Microsatellite-Stable Colorectal Cancer: Insights from ESMO Congress
Recent advancements in the treatment of advanced/metastatic microsatellite-stable (MSS) colorectal cancer (CRC) hold promising implications for improved patient outcomes. At the European Society for Medical Oncology (ESMO) Congress, Adagene presented compelling results demonstrating the efficacy of ADG126, an anti-CTLA-4 SAFEbody, when combined with pembrolizumab (KEYTRUDA). Notably, the confirmed partial responses (PRs) doubled since the ASCO GI report. This article explores the clinical data, potential therapeutic benefits, and broader implications of this treatment combination.
Colorectal cancer remains a significant cause of morbidity and mortality worldwide, with MSS CRC posing unique therapeutic challenges due to its relative resistance to immunotherapies. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has emerged as a critical therapeutic target within the immune checkpoint pathway, aimed at enhancing antitumor immunity. ADG126, an innovative anti-CTLA-4 SAFEbody, has been combined with pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, to explore synergistic potential in treating MSS CRC.
Study Design and Methods
The clinical study presented at the ESMO Congress focused on a cohort of 17 patients with advanced or metastatic MSS CRC, receiving ADG126 at a dosage of 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab. Patients were rigorously assessed for overall response rate (ORR), partial responses (PRs), and treatment-related adverse events. The primary endpoint was to evaluate the efficacy and safety profile of this combination therapy.
Results
Response Rates and Efficacy
- ’Overall Response Rate (ORR):’ The overall response rate reached 24% (4 out of 17 patients), showcasing a significant increase in confirmed partial responses (PRs) since the last ASCO Gastrointestinal Cancers Symposium.
- ’Partial Responses (PRs):’ The confirmed partial responses doubled, highlighting four PRs in this latest cohort, compared to previous reports.
- ’Patient Subsets:’ It is noteworthy that the improved ORR was observed specifically in MSS CRC patients without liver and peritoneal metastases.
Safety and Tolerability
- ’Adverse Events:’ The combination therapy was generally well-tolerated, with a manageable safety profile aligning well with known adverse events of CTLA-4 and PD-1 inhibitors.
- ’Treatment Discontinuation:’ No patients discontinued treatment due to adverse events, indicating a high level of tolerance and potential for continued treatment.
Discussion
Mechanism of Action
ADG126 operates as a SAFEbody, designed to selectively target CTLA-4 expressed in the tumor microenvironment, minimizing systemic exposure and thereby reducing the likelihood of immune-related adverse effects. Pembrolizumab, on the other hand, inhibits PD-1, preventing the deactivation of cytotoxic T-cells. This dual approach potentiates an enhanced immune-mediated antitumor response.
Clinical Implications
The results presented at the ESMO Congress suggest that combining ADG126 with pembrolizumab could represent a transformative therapeutic strategy for MSS CRC patients, particularly those without liver and peritoneal metastases. The doubling of confirmed PRs illustrates a robust in vivo antitumor activity, establishing a credible basis for further clinical trials.
Future Directions
To solidify these findings, subsequent studies with larger patient cohorts and extended follow-up periods are recommended. Fractionation schedules, dosing optimizations, and combination with other novel agents could further refine the therapeutic landscape for MSS CRC.
Conclusion
The promising results of ADG126 in combination with pembrolizumab underscore the potential for substantial advancements in the treatment of advanced/metastatic MSS colorectal cancer. As partial responses continue to increase, and treatment regimens evolve, the therapeutic horizon for MSS CRC appears increasingly optimistic.
References
- ESMO Congress 2023 presentations and abstracts.
- ASCO Gastrointestinal Cancers Symposium reports.Title
Doubling the Hope: Breakthrough Anti-CTLA-4 SAFEbody Combination Shows Promise in Advanced MSS Colorectal Cancer Treatments’
Comments